Orthocell Ltd ( (AU:OCC) ) has issued an announcement.
Orthocell Limited has appointed its first four US distributors for its nerve repair product, Remplir™, following its recent FDA 510(k) clearance. This strategic move allows Orthocell to enter the US$1.6 billion US nerve repair market, with initial sales expected soon. The company plans to expand its distributor network to approximately 10 by mid-2025, covering around 25 states, to accelerate market penetration and revenue growth. Orthocell’s strong financial position and existing inventory support its US rollout, positioning it well for success in the competitive nerve repair industry.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company focused on developing and commercializing innovative products for the repair and regeneration of damaged tissues. Its primary product, Remplir™, is a collagen wrap used in nerve repair surgery. The company is targeting the global nerve repair market, which is estimated to be worth over US$3.5 billion.
YTD Price Performance: -4.78%
Average Trading Volume: 1,532,055
Technical Sentiment Signal: Sell
Current Market Cap: A$313.4M
See more data about OCC stock on TipRanks’ Stock Analysis page.